VMAT2 Inhibitor Compounds Reducing Off-Target Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current VMAT2 inhibitors, such as tetrabenazine, have side effects like sedation, depression, and Parkinsonism due to off-target activity, and there is a need for improved compounds that effectively target VMAT2 without these adverse effects.
Innovation Solution
Development of specific VMAT2 inhibitor compounds, including those of Formula (I) and their pharmaceutically acceptable salts, solvates, and hydrates, which are designed to selectively inhibit VMAT2 with reduced off-target activity, formulated for use in pharmaceutical compositions to treat neurological and psychiatric disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tetrabenazine is used to inhibit VMAT2, then VMAT2 inhibition efficacy is improved, but off-target activity increases causing side effects
Solution Approach 1:
The patent applies local quality by modifying specific regions of the tetrabenazine molecule (positions R1, R2, R3, R4) to create compounds with differentiated properties. Each substituent position can be independently optimized to enhance VMAT2 selectivity while reducing off-target activity, allowing different parts of the molecule to contribute differently to the overall therapeutic profile.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical substituents at multiple positions on the core isoquinoline structure. By changing parameters such as substituent type, position, and configuration, the invention optimizes the balance between VMAT2 inhibition potency and selectivity, reducing side effects like sedation and Parkinsonism while maintaining therapeutic efficacy.
2Reliability
If VMAT2 inhibition is strengthened to treat hyperkinetic disorders, then therapeutic effectiveness is improved, but risk of Parkinsonism and depression increases
Solution Approach 1:
The patent applies segmentation by dividing the molecule into distinct functional regions (core isoquinoline structure, N-substituent, and aromatic substituents at positions R1-R4). This allows independent optimization of each segment to achieve potent VMAT2 inhibition while minimizing harmful effects on other neurotransmitter systems, thereby reducing the risk of Parkinsonism and depression.
Solution Approach 2:
The patent uses specific substituent groups as intermediaries that mediate between VMAT2 binding affinity and selectivity. These intermediary chemical groups at positions R1-R4 facilitate optimal interaction with VMAT2 while preventing unwanted interactions with other targets, thus achieving therapeutic effectiveness without increasing the risk of adverse effects.
3Object-affected harmful factors
If compound selectivity is increased to reduce side effects, then safety is improved, but complexity of compound structure increases
Solution Approach 1:
The patent applies universality by designing a core isoquinoline structure that serves multiple functions: providing the essential VMAT2 binding scaffold while accommodating various substituents that fine-tune selectivity and pharmacokinetic properties. This multi-functional core structure allows for simplified optimization compared to completely novel molecular frameworks.
Solution Approach 2:
The patent employs partial action by introducing substituents only at specific positions (R1-R4) on the core structure rather than modifying the entire molecule. This selective substitution approach achieves the necessary selectivity and safety profile without unnecessarily increasing molecular complexity, maintaining synthetic feasibility and pharmacological optimality.
Data Source
AI summary
Provided is a compound selected from compounds of Formula (I) and pharmaceutically acceptable salts, solvates, and hydrates thereof: (I) wherein R1, R2, R3 and R4 are as defined herein. Such compounds are inhibitors of the vesicular monoamine transporter 2 (VMAT2) and have utility for treating, for example, neurological and psychiatric diseases and disorders. Also disclosed are compositions containing such compounds in combination with a pharmaceutically acceptable carrier, as well as methods relating to their use in subjects in need thereof.